Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts you...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Maria Grazia, Bocchetti, Marco, Riccardi, Claudia, Trifuoggi, Marco, Paduano, Luigi, Montesarchio, Daniela, Misso, Gabriella, Santamaria, Rita, Piccolo, Marialuisa, Irace, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/
https://www.ncbi.nlm.nih.gov/pubmed/37047448
http://dx.doi.org/10.3390/ijms24076473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/
https://www.ncbi.nlm.nih.gov/pubmed/37047448
http://dx.doi.org/10.3390/ijms24076473

Ejemplares similares